Transaction Overview In January 2021, Rosetta Capital completed a secondary transaction to acquire a portfolio of seven life sciences assets from Schroder UK Public Private Trust plc, an large UK-based investment trust, for a total acquisition price of £49.0 million with an agreement to provide follow-on capital to support those companies through value creation. The …
Transaction Overview Rosetta Capital completed a secondary transaction to acquire a portfolio of over 20 North American and European life sciences assets from a Corporate Venture Capital arm of a Top 10 Pharma company. This enabled the Corporate Venture Capital arm to redeploy capital into assets that aligned strategically with the parent company. Selected exits …
Transaction Overview Rosetta Capital completed a secondary transaction involving debt and equity to secure a portfolio of US and Canadian life sciences assets from GrowthWorks, a Canadian fund manager. Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience. All3 Exited Private Public …
Transaction Overview In February 2013, Rosetta Capital completed a secondary transaction to acquire a portfolio of thirteen life sciences assets from Karolinska Development, the investment arm of Karolinska Institutet, a leading university in Sweden. The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, …
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
